El interés en corto de Johnson & Johnson da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Johnson & Johnson. Los datos de interés en corto se actualizan cada dos semanas.

Johnson & Johnson (NYSE:JNJ) Bolsa, Informe de interés en corto

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

JOHNSON & JOHNSON ORD

President-elect Donald Trump picked Robert F. Kennedy Jr., known for his vaccine skepticism, as his nominee Thursday to lead the <a href="https://www.benzinga.com/general/biotech/24/10/41127143/us-hhs-reveal-cost-savings-for-54-prescription-drugs-including-novartis-cancer-drug-ozempic-could">Department of Health and Human Services. </a>
This move, which comes after Kennedy ended his presidential campaign and endorsed Trump, positions the environmental activist to potentially reshape national health policies. The selection has stirred mixed reactions, particularly from public health experts, <a href="https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617">Politico</a> reports.
&#8220;For too long, Americans have been crushed by the industrial food complex and drug companies who have engaged in deception, misinformation, and disinformation when it comes to Public Health,&#8221; Trump said in a tweet announcing the decision. 
As Benzinga reported earlier this month, Kennedy has a history of spreading falsehoods about vaccines, including that they cause autism, a theory disproven by scientific studies. His selection as the nominee for HHS secretary comes against a backdrop of falling vaccination rates, which coincide with, in one example, 13 measles outbreaks in the U.S. so far this year. 
What Happened: Trump's decision is part of a broader promise to "let Kennedy go wild" with health and food policies, aiming to overhaul the HHS. Kennedy has expressed sharp criticisms of several health agencies.
Kennedy had hinted at the potential role of "health czar" in Trump&#8217;s administration. If he is confirmed, Kennedy's appointment could influence vaccine policy and the <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">direction of the CDC, FDA, and NIH.</a>
Also Read: <a href="https://www.benzinga.com/trading-ideas/24/11/41977313/will-trumps-election-win-push-sp-500-even-higher-in-final-weeks-of-2024-over-75-say">Will Trump&#8217;s Election Win Push S&amp;P 500 Even Higher In Final Weeks Of 2024? Over 75% Say&#8230;</a>
Kennedy's prospective role has already affected vaccine manufacturer stocks. Major vaccine-related companies saw declines in stock prices on Thursday due to the uncertainty surrounding Kennedy&#8217;s influence on health policy.
Key companies impacted include:
<ul>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) down 5.62% to $39.77.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) down 2.62% to $26.02.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) down 0.89% to $151.87.</li>
<li>AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) down 0.38% to $65.04.</li>
<li>Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) down 7.02% to $7.22.</li>
</ul>
Why It Matters: Kennedy's views on vaccines and health oversight agencies stand in stark contrast to established medical consensus. His appointment could alter public health directives, with some analysts predicting potential shifts in FDA regulatory independence and vaccine guidelines. 
The impact may extend beyond policy, shaping public trust in health systems amid ongoing debates over vaccine safety.
Kennedy, while indicating he has no plans to "take away anybody's vaccines," continues to be a polarizing figure. Vaccine-related stocks may experience ongoing volatility as the Trump administration finalizes its health policy agenda.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock.

Equities

Government

News

Regulations

Health Care

Politics

Markets

Movers

MRNA

NVAX

Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower

Biotech

General

Johnson & Johnson's Nipocalimab Achieves Over 77% IgG Reduction And Significant Clinical Improvement In Phase 2 Sjögren's Disease Study; Gains FDA Breakthrough Therapy Designation

Johnson & Johnson MedTech Announces Exclusive Commericla Distribution Agreement In U.S. With Responsive Arthroscopy To Expand Sports Soft Tissue Solution

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) has filed a lawsuit against a U.S. government agency over a contentious <a href="https://www.benzinga.com/topic/pharmaceuticals">disagreement about payment methods</a>.
What Happened: The legal spat stems from the federal 340B Drug Pricing Program, which provides discounted medications to hospitals <a href="https://www.benzinga.com/general/biotech/24/08/40560227/johnson-johnson-aims-new-policy-for-hospital-payments-under-340b-drug-discount-program-related-to" target="_blank" rel="noreferrer noopener">serving vulnerable patients</a>.
The pharmaceutical giant <a href="https://fingfx.thomsonreuters.com/gfx/legaldocs/egvbjoronvq/JJ%20Health%20Care%20Systems%20v%20Becerra%2020241112.pdf" target="_blank" rel="noreferrer noopener">argues</a> that the program has strayed from its original intent and has become dominated by well-funded hospitals and for-profit entities. This includes large pharmacy chains and pharmacy benefit managers, leading to abuses that undermine patient benefits.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40316445/medicare-costs-for-johnson-johnsons-psoriasis-drug-stelara-double-when-obtained-at-pharmacies" rel="noreferrer noopener">Medicare Costs For Johnson &amp; Johnson&#8217;s Psoriasis Drug Stelara Double When Obtained at Pharmacies</a>
The 340B Program was established in 1992. It was designed to support low-income and uninsured patients by enabling certain healthcare providers to purchase outpatient drugs at reduced prices.
Manufacturers must enter a Pharmaceutical Pricing Agreement (PPA) with the Department of Health and Human Services (HHS) to sell drugs at discounted rates. This allows them to qualify for Medicare and Medicaid reimbursements.
However, Johnson &amp; Johnson contends that the program, now the second-largest federal drug initiative after Medicare, has been exploited by entities not intended initially as beneficiaries, sidelining patients.
In August 2024, Johnson &amp; Johnson proposed a new rebate-based pricing model in response to growing concerns over program integrity.
This model would shift from upfront discounts to rebates issued upon verification of purchase and dispense data, aimed at curbing duplicate discounting and improving transparency.
Initially, the rebate model would apply only to two of Johnson &amp; Johnson&#8217;s drugs and to disproportionate share hospitals (DSH)—large, resource-rich hospitals that, despite comprising less than 10% of covered entities, account for nearly 78% of 340B purchases.
Why It Matters: Johnson &amp; Johnson points to findings from audits conducted by the Health Resources and Services Administration (HRSA), which revealed significant non-compliance by covered entities, including unauthorized use of 340B-priced drugs and duplicate discounts.
From 2012 to 2019, HRSA audits found hundreds of violations involving diversion of drugs and overlapping Medicaid rebates.
Johnson &amp; Johnson&#8217;s attempts to audit covered entities also met resistance, with several refusing to produce records despite statutory obligations, further highlighting program abuses.
However, HRSA resisted the plan, threatening to terminate Johnson &amp; Johnson&#8217;s PPA and impose significant penalties. This prompted the company to suspend the model&#8217;s implementation, citing HRSA&#8217;s &#8220;severe and disproportionate&#8221; sanctions. Johnson &amp; Johnson argues that HRSA&#8217;s stance contradicts statutory provisions and the agency&#8217;s stated goals for program transparency.
Johnson &amp; Johnson&#8217;s lawsuit seeks a declaration that HRSA&#8217;s attempts to block the rebate model are unlawful and an injunction to prevent enforcement actions related to the proposed model.
The company emphasizes that program abuses will continue without adjustments like its rebate plan at the expense of the patients it was meant to serve.
Price Action: Johnson &amp; Johnson stock is down 0.37% at $152.08 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41932978/cisco-and-ltimindtree-join-forces-to-fortify-hybrid-work-security-with-cutting-edge-solutions" target="_blank" rel="noreferrer noopener">Cisco And LTIMindtree Join Forces To Fortify Hybrid Work Security with Cutting-Edge Solutions</a></li>
</ul>

Large Cap

Legal

Johnson & Johnson Challenges Government Drug Pricing Dispute Over Two Drugs

The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent autoantibody disease with no approved advanced therapies, is supported by results from the Phase 2 DAHLIAS study
A greater than 70 percent relative improvement in systemic disease activity at Week 24 was demonstrated in study participants on average who received nipocalimab 15 mg/kg compared to participants who received placebo
Nipocalimab was granted BTD in hemolytic disease of the fetus and newborn earlier this year, making this the second time Johnson &amp; Johnson's nipocalimab has received this designation
SPRING HOUSE, Pa., Nov. 11, 2024 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced that the U.S. Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy designation (BTD) for the treatment of adults living with moderate-to-severe Sjögren's disease (SjD), a debilitating and chronic autoantibody disease with high prevalence, for which no approved advanced treatments are available.1,2,3,4 Nipocalimab is the only investigational therapy to secure this designation in SjD. This regulatory milestone is the second time BTD has been granted for nipocalimab; the first was granted <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4299694-1&amp;h=1171220494&amp;u=https%3A%2F%2Fwww.jnj.com%2Fmedia-center%2Fpress-releases%2Fjohnson-johnsons-nipocalimab-granted-u-s-fda-breakthrough-therapy-designation-for-the-treatment-of-individuals-at-high-risk-for-severe-hemolytic-disease-of-the-fetus-and-newborn-hdfn&amp;a=in+February">in February</a> for the treatment of alloimmunized&nbsp;pregnant individuals at high risk of severe hemolytic disease of the fetus and newborn (HDFN).

Johnson & Johnson Today Announces That The U.S. FDA Has Granted Nipocalimab Breakthrough Therapy Designation For The Treatment Of Adults Living With Moderate-To-Severe Sjögren's Disease, A Debilitating And Chronic Autoantibody Disease With High Prevalence, For Which No Approved Advanced Treatments Are Available

Johnson & Johnson Submits Regulatory Applications To FDA And EMA Seeking Approval Of A New Indication Of DARZALEX FASPRO In The US And DARZALEX Subcutaneous Formulation In The EU

In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and its primary competitors in the Pharmaceuticals industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>Johnson &amp; Johnson Background</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johnson &amp; Johnson</td>
<td>26.10</td>
<td>5.42</td>
<td>4.37</td>
<td>3.8%</td>
<td>$5.38</td>
<td>$15.51</td>
<td>5.25%</td>
</tr>
<tr>
<td>Eli Lilly and Co</td>
<td>83.66</td>
<td>51.76</td>
<td>17.18</td>
<td>6.98%</td>
<td>$2.25</td>
<td>$9.27</td>
<td>20.43%</td>
</tr>
<tr>
<td>Novo Nordisk AS</td>
<td>33.90</td>
<td>26.54</td>
<td>11.87</td>
<td>18.97%</td>
<td>$35.74</td>
<td>$57.79</td>
<td>25.34%</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>18.64</td>
<td>4.93</td>
<td>4.39</td>
<td>7.5%</td>
<td>$5.61</td>
<td>$9.94</td>
<td>8.93%</td>
</tr>
<tr>
<td>AstraZeneca PLC</td>
<td>30.99</td>
<td>5.01</td>
<td>4.06</td>
<td>5.01%</td>
<td>$4.12</td>
<td>$10.76</td>
<td>13.33%</td>
</tr>
<tr>
<td>Pfizer Inc</td>
<td>36.48</td>
<td>1.68</td>
<td>2.61</td>
<td>4.96%</td>
<td>$7.25</td>
<td>$12.44</td>
<td>31.2%</td>
</tr>
<tr>
<td>Zoetis Inc</td>
<td>32.02</td>
<td>14.69</td>
<td>8.51</td>
<td>13.37%</td>
<td>$1.05</td>
<td>$1.69</td>
<td>11.02%</td>
</tr>
<tr>
<td>GSK PLC</td>
<td>22.67</td>
<td>4.01</td>
<td>1.82</td>
<td>-0.41%</td>
<td>$1.17</td>
<td>$5.62</td>
<td>-1.66%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Co Ltd</td>
<td>22.96</td>
<td>0.96</td>
<td>1.46</td>
<td>1.25%</td>
<td>$380.28</td>
<td>$781.73</td>
<td>12.75%</td>
</tr>
<tr>
<td>Dr Reddy's Laboratories Ltd</td>
<td>19.30</td>
<td>3.49</td>
<td>3.55</td>
<td>4.18%</td>
<td>$23.9</td>
<td>$47.77</td>
<td>16.51%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals PLC</td>
<td>18.88</td>
<td>1.83</td>
<td>2</td>
<td>4.52%</td>
<td>$0.36</td>
<td>$0.91</td>
<td>6.95%</td>
</tr>
<tr>
<td>Corcept Therapeutics Inc</td>
<td>43.05</td>
<td>8.90</td>
<td>9.61</td>
<td>7.56%</td>
<td>$0.05</td>
<td>$0.18</td>
<td>47.69%</td>
</tr>
<tr>
<td>Organon &amp; Co</td>
<td>3.13</td>
<td>8.25</td>
<td>0.64</td>
<td>112.72%</td>
<td>$0.4</td>
<td>$0.92</td>
<td>4.15%</td>
</tr>
<tr>
<td>Prestige Consumer Healthcare Inc</td>
<td>18.98</td>
<td>2.29</td>
<td>3.50</td>
<td>2.94%</td>
<td>$0.08</td>
<td>$0.15</td>
<td>-4.36%</td>
</tr>
<tr>
<td>Average</td>
<td>29.59</td>
<td>10.33</td>
<td>5.48</td>
<td>14.58%</td>
<td>$35.56</td>
<td>$72.24</td>
<td>14.79%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>By closely studying Johnson &amp; Johnson, we can observe the following trends: 
<ul>
<li>
With a Price to Earnings ratio of 26.1, which is 0.88x less than the industry average, the stock shows potential for growth at a reasonable price, making it an interesting consideration for market participants.
</li>
<li>
The current Price to Book ratio of 5.42, which is 0.52x the industry average, is substantially lower than the industry average, indicating potential undervaluation.
</li>
<li>
Based on its sales performance, the stock could be deemed undervalued with a Price to Sales ratio of 4.37, which is 0.8x the industry average.
</li>
<li>
The company has a lower Return on Equity (ROE) of 3.8%, which is 10.78% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.
</li>
<li>
The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $5.38 Billion is 0.15x below the industry average, suggesting potential lower profitability or financial challenges.
</li>
<li>
With lower gross profit of $15.51 Billion, which indicates 0.21x below the industry average, the company may experience lower revenue after accounting for production costs.
</li>
<li>
The company is witnessing a substantial decline in revenue growth, with a rate of 5.25% compared to the industry average of 14.79%, which indicates a challenging sales environment.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730991650_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio gauges the extent to which a company has financed its operations through debt relative to equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In terms of the Debt-to-Equity ratio, Johnson &amp; Johnson stands in comparison with its top 4 peers, leading to the following comparisons:
<ul>
<li>
Johnson &amp; Johnson is in a relatively stronger financial position compared to its top 4 peers, as evidenced by its lower debt-to-equity ratio of 0.51.
</li>
<li>
This implies that the company relies less on debt financing and has a more favorable balance between debt and equity.
</li>
</ul>
<h3>Key Takeaways</h3>
For Johnson &amp; Johnson, the PE, PB, and PS ratios are all low compared to its peers in the Pharmaceuticals industry, indicating potential undervaluation. However, the low ROE, EBITDA, gross profit, and revenue growth suggest that the company may be facing challenges in generating profits and growth compared to its industry counterparts. This could be a concern for investors looking for higher returns.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Industry Comparison: Evaluating Johnson &amp; Johnson Against Competitors In Pharmaceuticals Industry

Guggenheim analyst Vamil Divan maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Neutral and raises the price target from $156 to $162.

Price Target

Analyst Ratings

Guggenheim Maintains Neutral on Johnson & Johnson, Raises Price Target to $162

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>)</h3>
<ul>
<li>Dividend Yield: 3.05%</li>
<li>Citigroup analyst Andrew Baum maintained a Buy rating and cut the price target from $60 to $40 on Oct. 25. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Overweight rating and raised the price target from $48 to $51 on July 11. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Nov. 4, Royalty Pharma and Syndax Pharmaceuticals entered into $350 million royalty funding agreement for Niktimvo.</li>
<li>Benzinga Pro's real-time newsfeed alerted to l<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">atest RPRX news. </a></li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/21cac52e-a5a5-4623-954e-111f57f53a6d" alt="" style="width:638px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</h3>
<ul>
<li>Dividend Yield: 3.13%</li>
<li>Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $180 to $185 on Oct. 16. This analyst has an accuracy rate of 77%.</li>
<li>Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and increased the price target from $163 to $166 on Oct. 16. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On Oct. 28, Johnson &amp; Johnson announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn's disease.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"> latest JNJ news.</a> </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/572ca32b-5a3e-4fc3-b873-df0527702e1f" alt="" style="width:659px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)</h3>
<ul>
<li>Dividend Yield: 3.12%</li>
<li>Truist Securities analyst Richard Newitter maintained a Hold rating and raised the price target from $90 to $93 on Oct. 14. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Joanne Wuensch maintained a Neutral rating and increased the price target from $85 to $92 on Oct. 1. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: Medtronic will report financial results for its second quarter of fiscal year 2025 on Tuesday, Nov. 19.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">trend in MDT stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png" alt="" class="wp-image-632327" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-768x713.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a>

Dividends

Pre-Market Outlook

RPRX

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

The global <a href="https://www.benzinga.com/markets/psychedelics">psychedelic drugs market</a> is set for rapid expansion, with projections forecasting growth from $4.88 billion in 2023 to $10.2 billion by 2028, <a href="https://www.einpresswire.com/article/754811757/global-psychedelic-drugs-market-outlook-2024-2033-growth-drivers-share-and-trends">according</a> to The Business Research Company. With a compound annual growth rate of 16.1%, this rise is largely driven by increased awareness of mental health needs, progressive regulatory shifts and the medical community's growing acceptance of <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelics for therapeutic applications</a>.
<h3 class="wp-block-heading">Key Market Drivers: Mental Health Awareness And Regulatory Changes</h3>
The surge in mental health disorders, including <a href="https://www.benzinga.com/topic/treatment-resistant-depression">treatment-resistant depression</a> and <a href="https://www.benzinga.com/topic/ptsd">PTSD</a>, is fueling demand for alternative treatments like psychedelics. "Psychedelic drugs are utilized for treating depression and PTSD, contributing to a decrease in mental health issues," notes The Business Research Company. Psychedelics such as <a href="https://www.benzinga.com/topic/lsd">LSD</a>, <a href="https://www.benzinga.com/topic/ketamine">ketamine</a>, and newer innovations like depression-targeting nasal sprays are becoming prominent options for patients and providers alike.
<h3 class="wp-block-heading">Trends Shaping The Psychedelic Drugs Market</h3>
Key trends include a focus on public education, regulatory adaptation, and diversification of compounds. Companies such as Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Mydecine Innovations Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MYCOF#OTC">MYCOF</a>) are actively advancing in this sector to develop treatments that cater to evolving patient needs. North America currently leads the market, with Asia-Pacific expected to see the fastest growth through 2033 due to increasing <a href="https://www.benzinga.com/markets/cannabis/23/12/36107955/japan-approves-marijuana-derived-medicines-adopt-7-year-prison-sentences-for-recreational-use">policy changes</a> and investment in mental health infrastructure.
<h3 class="wp-block-heading">Market Segmentation: Psychedelic Compounds And Indications</h3>
The market includes various types of psychedelics categorized by drug (LSD, ketamine, GHB), indication (depression, PTSD) and origin (natural or synthetic). Applications range from treatment-resistant depression to panic disorders, with distribution spanning hospitals, retail and online pharmacies.
<h3 class="wp-block-heading">Outlook And Opportunities For Psychedelic Drug Developers</h3>
As research continues to support psychedelics&#8217; benefits in mental health treatment, companies are poised to capitalize on both emerging treatment areas and regional growth opportunities. With major pharmaceutical players investing in these compounds, the market is expected to become increasingly competitive and patient-focused, highlighting a promising outlook for psychedelic treatments.
Cover image made with AI

Cannabis

Psychedelics

MYDECINE INNOV GRP by MYDECINE INNOVATIONS GROUP INC.

MYCOF

Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises

GOOG

GOOGL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Google To Launch New "Sexual Health & Wellness" Policy On November 11, Permitting Promotion Of Personal Lubricants And Prescription Drugs In Select Countries

On Monday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced results from the Phase 3 GRAVITI study of Tremfya&nbsp;(guselkumab) for Crohn&#8217;s disease.
The findings demonstrated significant clinical remission and endoscopic response at 48 weeks in adults with moderately to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41570497/tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-demonstrate-robust-results-with-a-full" rel="noreferrer noopener">severely active Crohn&#8217;s disease</a>.
These results are among the 14 Johnson &amp; Johnson abstracts presented at the American College of Gastroenterology 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41552265/johnson-johnsons-blockbuster-drug-tremfya-clears-plaque-psoriasis-with-lesions-covering-bodys-sma" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body&#8217;s Smaller Areas</a>.
GRAVITI &nbsp;Subcutaneous Induction Week 12 Results:
<ul>
<li>More than half of patients treated with Tremfya (400 mg administered subcutaneously at Weeks 0, 4, and 8) achieved clinical remission versus those in the placebo group (56.1% versus 21.4%).</li>
<li>Endoscopic response was achieved in 41.3% of patients treated with Tremfya SC induction therapy versus 21.4% in the placebo group.</li>
<li>Greater improvements in clinical remission were seen as early as Week 4 with Tremfya compared with placebo, demonstrating rapid onset of action.</li>
</ul>
GRAVITI SC Induction Week 48 Results:
<ul>
<li>The rate of clinical remission was more than three times higher with both maintenance doses of Tremfya versus placebo (60% for 100 mg SC every eight weeks (q8w) and 66.1% for 200 mg SC every four weeks (q4w) versus 17.1%.</li>
<li>The endoscopic response was achieved in 44.3% and 51.3% of patients in the Tremfya 100 mg SC q8w group and 200 mg SC q4w group, respectively, versus 6.8% in the placebo group.</li>
<li>Endoscopic remission was achieved in 30.4% and 38.3% of patients in the Tremfya 100 mg SC q8w group and 200 mg SC q4w group, respectively, versus 6.0 percent in the placebo group.</li>
</ul>
The FDA approved Tremfya in&nbsp;September 2024&nbsp;for moderately to severely active ulcerative colitis (UC), and an application for moderately to severely active Crohn&#8217;s disease is currently under FDA review.
Regulatory applications seeking approval of Tremfya for moderately to severely active ulcerative colitis and Crohn&#8217;s disease have been submitted in&nbsp;Europe.
Price Action: JNJ stock is up 0.29% at $161.34 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41574625/corning-and-at-t-sign-1-billion-deal-to-supercharge-fiber-network" target="_blank" rel="noreferrer noopener">Corning And AT&amp;T Sign $1 Billion+ Deal To Supercharge Fiber Network</a></li>
</ul>
Photo via Shutterstock

Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease

GRAVITI SC Induction Week 12 Results:
<ul>
<li>More than half of patients treated with TREMFYA (400 mg administered subcutaneously at Weeks 0, 4, and 8) achieved clinical remission versus those in the placebo group (56.1 percent versus 21.4 percent).</li>
<li>Endoscopic response was achieved in 41.3 percent of patients treated with TREMFYA SC&nbsp;induction therapy versus 21.4 percent in the placebo group.</li>
<li>Greater improvements in clinical remission were seen as early as Week 4 with TREMFYA&nbsp;compared with placebo, demonstrating rapid onset of action.</li>
</ul>
GRAVITI SC Induction Week 48 Results:
<ul>
<li>The rate of clinical remission was more than three times higher with both maintenance doses of&nbsp;TREMFYA versus placebo (60.0 percent for 100 mg SC every eight weeks (q8w) and 66.1 percent for 200 mg SC every four weeks (q4w) versus 17.1 percent.</li>
<li>Endoscopic response was achieved in 44.3 percent and 51.3 percent of patients in the&nbsp;TREMFYA 100 mg SC q8w group and 200 mg SC q4w group respectively versus 6.8 percent in the placebo group.</li>
<li>Endoscopic remission was achieved in 30.4 percent and 38.3 percent of patients in the TREMFYA 100 mg SC q8w group and 200 mg SC q4w group respectively versus 6.0 percent in the placebo group.</li>
</ul>

Johnson & Johnson Announced Results From Phase 3 GRAVITI Study Of Tremfya (Guselkumab), Demonstrating Significant Clinical Remission And Endoscopic Response At 48 Weeks In Adults With Moderately To Severely Active Crohn's Disease

On Friday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced that treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41542780/new-spectrem-study-findings-reveal-tremfya-guselkumab-effectively-clears-overlooked-and-undertreat" rel="noreferrer noopener">failed topical treatment</a>.&nbsp;&nbsp;
Data from the Phase 3b SPECTREM study to measure skin clearance and other treatment outcomes in low BSA moderate PsO with involvement across four special sites (scalp, face, skin folds, and genitals) and previous topical treatment failure were presented at the 2024 Fall Clinical Dermatology Conference.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41466839/justice-departments-trustee-program-alleges-johnson-johnsons-talc-litigation-bankruptcy-bid-is-ba" rel="noreferrer noopener">Justice Department&#8217;s Trustee Program Alleges Johnson &amp; Johnson&#8217;s Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability</a>
A significantly greater proportion of patients who received Tremfya achieved the primary endpoint of an Investigator&#8217;s Global Assessment (IGA) score of cleared (0) or minimal disease compared to those who received placebo (74.2% versus 12.4%, respectively.
Significant clearance versus placebo at Week 16: scalp (75.0% versus 14.5%), face (87.8% versus 28.6%), intertriginous (86.5% versus 28.8%), and genital (78.0% versus 37.5%).
Complete clearance of each special site was consistently achieved in the majority of patients who received Tremfya versus placebo: scalp (60.3% versus 9.3%), face (75.7% versus 23.9%), intertriginous (76.6% versus 24.2%) and genital (72.7% versus 32.7%).
Statistically significant improvements were also achieved across all major secondary endpoints, including:
52.9% achieved a Psoriasis Area Severity Index (PASI) 90 response compared to 6.2% of participants who received a placebo (p&lt;0.001).
The average patient saw over 80% improvement from baseline for BSA and PASI compared to those who received placebo (80.6% versus 6.1% and 82.6% versus 13.7%, respectively; p&lt;0.001).
In the third quarter, Tremfya generated global sales of $1.01 billion, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41329767/johnson-johnsons-q3-earnings-revenue-and-eps-beat-on-strong-cancer-drug-sales-revises-annual-outl" rel="noreferrer noopener">13% year over year</a>.
Last month, the FDA approved Tremfya for adults with moderately to severely active ulcerative colitis, a chronic disease of the large intestine in which the colon<a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40823500/tremfya-guselkumab-receives-u-s-fda-approval-for-adults-with-moderately-to-severely-active-ulcerat" rel="noreferrer noopener"> lining becomes inflamed</a>.
The European Medicines Agency is reviewing Tremfya for adults with moderately to severely active <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41269501/tremfya-guselkumab-demonstrates-impressive-results-across-biologic-na-ve-and-biologic-refractory-p" rel="noreferrer noopener">ulcerative colitis and Crohn&#8217;s disease</a>.&nbsp;
Price Action: JNJ stock is down 1.49% at $161.23 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41550798/newell-brands-q3-earnings-margins-hit-highest-levels-since-2020-boosts-2024-eps-outlook-more" target="_blank" rel="noreferrer noopener">Newell Brands Q3 Earnings: Margins Hit Highest Levels Since 2020, Boosts 2024 EPS Outlook &amp; More</a></li>
</ul>
Photo via Wikimedia Commons

Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas

Launches Clinical Image Library To Aid Decision-Making For Diverse Skin Tones

Johnson & Johnson's SPECTREM Study Shows TREMFYA® (Guselkumab) Significantly Clears Low BSA Plaque Psoriasis In Special Sites; Achieves Primary And Secondary Endpoints In Phase 3b Trial

In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) alongside its primary competitors in the Pharmaceuticals industry. By meticulously examining crucial financial indicators, market positioning, and growth potential, we aim to provide valuable insights to investors and shed light on company's performance within the industry.
<h3>Johnson &amp; Johnson Background</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johnson &amp; Johnson</td>
<td>27.41</td>
<td>5.58</td>
<td>4.60</td>
<td>6.62%</td>
<td>$7.8</td>
<td>$15.58</td>
<td>4.31%</td>
</tr>
<tr>
<td>Eli Lilly and Co</td>
<td>111.24</td>
<td>59.97</td>
<td>20.97</td>
<td>22.5%</td>
<td>$4.12</td>
<td>$9.13</td>
<td>35.98%</td>
</tr>
<tr>
<td>Novo Nordisk AS</td>
<td>39.75</td>
<td>31.57</td>
<td>13.85</td>
<td>18.97%</td>
<td>$35.74</td>
<td>$57.79</td>
<td>25.34%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc</td>
<td>19.70</td>
<td>6.19</td>
<td>4.34</td>
<td>13.0%</td>
<td>$7.45</td>
<td>$12.37</td>
<td>7.16%</td>
</tr>
<tr>
<td>AstraZeneca PLC</td>
<td>37.35</td>
<td>6.04</td>
<td>4.89</td>
<td>5.01%</td>
<td>$4.12</td>
<td>$10.76</td>
<td>13.33%</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>23.33</td>
<td>5.53</td>
<td>4.82</td>
<td>7.97%</td>
<td>$5.25</td>
<td>$9.7</td>
<td>9.6%</td>
</tr>
<tr>
<td>Sanofi SA</td>
<td>29.11</td>
<td>1.69</td>
<td>2.59</td>
<td>1.53%</td>
<td>$2.03</td>
<td>$7.97</td>
<td>6.53%</td>
</tr>
<tr>
<td>Zoetis Inc</td>
<td>37.06</td>
<td>17.24</td>
<td>9.73</td>
<td>12.45%</td>
<td>$0.97</td>
<td>$1.69</td>
<td>8.3%</td>
</tr>
<tr>
<td>GSK PLC</td>
<td>12.96</td>
<td>4.15</td>
<td>1.68</td>
<td>8.32%</td>
<td>$2.31</td>
<td>$5.76</td>
<td>9.84%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Co Ltd</td>
<td>44.43</td>
<td>0.85</td>
<td>1.50</td>
<td>1.26%</td>
<td>$388.51</td>
<td>$821.04</td>
<td>14.11%</td>
</tr>
<tr>
<td>Dr Reddy's Laboratories Ltd</td>
<td>19.70</td>
<td>3.71</td>
<td>3.79</td>
<td>4.84%</td>
<td>$21.72</td>
<td>$46.34</td>
<td>13.87%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals PLC</td>
<td>18.84</td>
<td>1.82</td>
<td>1.99</td>
<td>4.52%</td>
<td>$0.36</td>
<td>$0.91</td>
<td>6.95%</td>
</tr>
<tr>
<td>Corcept Therapeutics Inc</td>
<td>42.53</td>
<td>8.42</td>
<td>9.35</td>
<td>6.14%</td>
<td>$0.04</td>
<td>$0.16</td>
<td>39.15%</td>
</tr>
<tr>
<td>Organon &amp; Co</td>
<td>4.44</td>
<td>30.77</td>
<td>0.70</td>
<td>203.12%</td>
<td>$0.43</td>
<td>$0.94</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Prestige Consumer Healthcare Inc</td>
<td>17.65</td>
<td>2.13</td>
<td>3.25</td>
<td>2.94%</td>
<td>$0.08</td>
<td>$0.15</td>
<td>-4.36%</td>
</tr>
<tr>
<td>Average</td>
<td>32.72</td>
<td>12.86</td>
<td>5.96</td>
<td>22.33%</td>
<td>$33.8</td>
<td>$70.34</td>
<td>13.27%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Upon a comprehensive analysis of Johnson &amp; Johnson, the following trends can be discerned: 
<ul>
<li>
At 27.41, the stock's Price to Earnings ratio is 0.84x less than the industry average, suggesting favorable growth potential.
</li>
<li>
The current Price to Book ratio of 5.58, which is 0.43x the industry average, is substantially lower than the industry average, indicating potential undervaluation.
</li>
<li>
Based on its sales performance, the stock could be deemed undervalued with a Price to Sales ratio of 4.6, which is 0.77x the industry average.
</li>
<li>
The company has a lower Return on Equity (ROE) of 6.62%, which is 15.71% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.
</li>
<li>
Compared to its industry, the company has lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $7.8 Billion, which is 0.23x below the industry average, potentially indicating lower profitability or financial challenges.
</li>
<li>
With lower gross profit of $15.58 Billion, which indicates 0.22x below the industry average, the company may experience lower revenue after accounting for production costs.
</li>
<li>
The company's revenue growth of 4.31% is significantly lower compared to the industry average of 13.27%. This indicates a potential fall in the company's sales performance.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729782055_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
By considering the Debt-to-Equity ratio, Johnson &amp; Johnson can be compared to its top 4 peers, leading to the following observations:
<ul>
<li>
Johnson &amp; Johnson demonstrates a stronger financial position compared to its top 4 peers in the sector.
</li>
<li>
With a lower debt-to-equity ratio of 0.58, the company relies less on debt financing and maintains a healthier balance between debt and equity, which can be viewed positively by investors.
</li>
</ul>
<h3>Key Takeaways</h3>
For Johnson &amp; Johnson in the Pharmaceuticals industry, the PE, PB, and PS ratios are all low compared to its peers, indicating potential undervaluation. However, the low ROE, EBITDA, gross profit, and revenue growth suggest underperformance relative to industry standards. This may signal a need for further investigation into the company's operational efficiency and growth strategies.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comparative Study: Johnson &amp; Johnson And Industry Competitors In Pharmaceuticals Industry

<a href="https://www.jnj.com/media-center/press-releases/darzalex-daratumumab-sc-based-quadruplet-regimen-approved-by-the-european-commission-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible#:~:text=BEERSE%2C%20BELGIUM%20(23%20October%202024,and%20dexamethasone%20(daratumumab%2DVRd)">https://www.jnj.com/media-center/press-releases/darzalex-daratumumab-sc-based-quadruplet-regimen-approved-by-the-european-commission-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible#:~:text=BEERSE%2C%20BELGIUM%20(23%20October%202024,and%20dexamethasone%20(daratumumab%2DVRd)</a>
<h2>Phase 3 PERSEUS study of daratumumab subcutaneous (SC) formulation in combination with bortezomib, lenalidomide and dexamethasone induction and consolidation, followed by daratumumab SC and lenalidomide maintenance showed a 58 percent reduction in risk of disease progression or death1 New regimen reinforces daratumumab SC as a foundational element for optimising frontline treatment of patients with newly diagnosed multiple myeloma, and significantly delaying disease progression2</h2>

Global

DARZALEX-SC Based Quadruplet Regimen Approved By The European Commission For Patients With Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible

The U.S. Trustee Program, a unit of the Department of Justice (DOJ) overseeing bankruptcy cases, has filed a motion in federal bankruptcy court in Houston to dismiss a Chapter 11 filing by a subsidiary of Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>).
The <a target="_blank" href="https://aboutblaw.com/bf1t" rel="noreferrer noopener">filing</a> aims to settle more than 60,000 talc-related lawsuits, marking J&amp;J's third attempt to pursue this strategy in as many years.
In September, Johnson &amp; Johnson reportedly increased its settlement offer by $1 billion, now totaling about $9 billion, to address claims that its talc baby powder&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40738358/johnson-johnson-raises-talc-settlement-offer-to-9b-moves-closer-to-settlement-victory" rel="noreferrer noopener">caused gynecological cancer</a>.
The DOJ argues that Johnson &amp; Johnson's latest bankruptcy maneuver is a bad-faith attempt to shield itself from billions in personal injury claims without actually entering bankruptcy.
The company's approach involves creating a new subsidiary, transferring billions in liabilities but few assets to this entity, and then filing for bankruptcy on its behalf.
This move is seen as a way for Johnson &amp; Johnson to secure a third-party release that would discharge both itself and the subsidiary from liability—an action that was expressly prohibited in a recent Supreme Court ruling.
Johnson &amp; Johnson has used similar tactics in the past, both dismissed due to findings of bad faith.
Despite these setbacks, the company has filed this new case under a different entity and jurisdiction, which the DOJ believes is an attempt to sidestep previous rulings.
The trustee's motion claims that the debtor in question has no valid reason for bankruptcy protection and that the filing serves no legitimate restructuring purpose.
The ongoing litigation stems from numerous claims that Johnson &amp; Johnson's talc-based products, including baby powder, caused personal injuries.
Many lawsuits assert a link between talc exposure and ovarian cancer, while others allege that the products were contaminated with asbestos, leading to mesothelioma.
J&amp;J has consistently denied these allegations.
As of October 2021, around 36,000 ovarian cancer claims and 470 mesothelioma cases were tied to Johnson &amp; Johnson's talc products, with many cases consolidated in a multi-district litigation in New Jersey.
Price Action: JNJ stock closed 0.38% at $163.45 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41463868/kimberly-clarks-growth-potential-underestimated-analyst-sees-attractive-entry-point" target="_blank" rel="noreferrer noopener">Kimberly-Clark's Growth Potential' Underestimated,' Analyst Sees Attractive Entry Point</a></li>
</ul>
Photo via Wikimedia Commons

Justice Department's Trustee Program Alleges Johnson & Johnson's Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability

Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) short percent of float has fallen 14.58% since its last report. The company recently reported that it has 19.74 million shares sold short, which is 0.82% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Johnson &amp; Johnson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729620922_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Johnson &amp; Johnson has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Johnson &amp; Johnson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Johnson &amp; Johnson's peer group average for short interest as a percentage of float is 4.55%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Johnson & Johnson's Recent Short Interest

Kenvue Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired <a href="https://www.benzinga.com/markets/equities/24/10/41419988/tylenol-listerine-maker-kenvue-under-activist-spotlight-with-starboard-value-stake-overhaul-ahea">a stake in the company</a>. 
The Details: According to the <a href="https://www.wsj.com/business/deals/activist-starboard-value-takes-stake-in-tylenol-maker-kenvue-cc3175bb">Wall Street Journal</a>, Starboard has acquired a &#8220;sizable&#8221; stake in Kenvue and is pushing for changes to boost the consumer-products company&#8217;s share price. The activist investor asserts that Kenvue has &#8220;some of the best consumer brands,&#8221; yet its stock has lagged behind its competitors for over a year.
Kenvue&#8217;s iconic brands include Aveeno, BAND-AID Brand, Johnson&#8217;s, Listerine, Neutrogena and Tylenol. Kenvue shares are up just 7% year-to-date compared to more than 23% gains in the S&amp;P 500. Competitors Haleon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) and Proctor and Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) have climbed 21% and 16%, respectively, since the start of the year.
The exact size of Starboard's position in Kenvue was not shared. Starboard&#8217;s specific turnaround ideas were also not reported, but people familiar with the matter said Starboard CEO Jeff Smith is expected to discuss more about Starboard&#8217;s perspective on Kenvue at the 13D Monitor Active-Passive Investor Summit in New York on Tuesday. 
According to a separate <a href="https://www.msn.com/en-us/money/companies/activist-starboard-could-push-for-kenvue-to-sell-some-all-of-its-sbh-business-analyst/ar-AA1sEH3C?ocid=finance-verthp-feeds">report</a>, Starboard may try to push the company to sell its skin, healthcare and beauty division in whole or part.
In a note released Monday, JPMorgan analyst Andrea Teixeira said, &#8220;Given the SHB segment has been a key area of debate on the stock over the past year and a half, we would expect Starboard to detail changes it would like to see management make to this division — which we suspect could involve divesting some/all of the segment.&#8221;
Kenvue was spun out of Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) last year. The company currently has a market cap of more than $41 billion, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Related Link: <a href="https://www.benzinga.com/news/24/10/41417197/elon-musk-tesla-refute-inefficiency-concerns-with-wireless-charging-on-cybercab-there-is-no-meaningf">Elon Musk, Tesla Refute Inefficiency Concerns With Wireless Charging On Cybercab: &#8216;There Is No Meaningful Efficiency Difference…&#8217;</a>
KVUE Price Action: At the time of publication, Kenvue stock was up 5.96% at $23.02, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: 3972315 from Pixabay.

KVUE

What's Going On With Kenvue Stock Monday?

Johnson & Johnson announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activ...

Johnson & Johnson announces results from analyses of Phase 2 DAHLIAS study

How To Build A $100,000 Dividend Portfolio: A Strategic Guide To Balance Income And Growth

Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson with an Outperform rating and $190 price target Published first o...

Johnson & Johnson initiated with an Outperform at Wolfe Research

Vaccine makers close lower amid reports RFK Jr may head HHS

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for portfolio protection. Thus, quality defensive stocks Johnson & Johnson (JNJ), Pfizer (PFE), and Genie Energy (GNE) could be ideal portfolio additions as market volatility rises. Continue reading... Defensive stocks are stocks of companies that deliver products and services of essential or <a href="https://www.investopedia.com/terms/d/defensivestock.asp">necessary nature like healthcare, medicines</a>, basic utilities, consumer goods, etc. The demand for such companies is the same through various business cycles, and therefore, they offer stable income and growth prospects to investors, making them ideal investment choices during market uncertainties.
Given this backdrop, it could be wise to invest in quality defensive stocks Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>), Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>), and Genie Energy Ltd. (<a href="https://stocknews.com/stock/GNE/">GNE</a>) for stability amid market volatility.
The U.S. economy has been showing mixed growth this year with each quarter. The economy grew at a 1.3% annualized rate in the first quarter, indicating slow expansion, whereas during the second quarter, the rate rose to 3.0%, fueled by strong household income growth and consumer spending.
Last week, the Bureau of Economic Analysis (BEA) <a href="https://www.commerce.gov/news/blog/2024/11/commerce-data-show-strong-economic-gains-due-americans-making-and-spending-more#:~:text=The%20U.S.%20Commerce%20Department's%20Bureau,Americans%20making%20and%20spending%20more.">reported GDP growth of 2.8%</a> at an annual rate in the third quarter of 2024, lower than the economists' estimate of 3.0%. The development during the quarter was driven by increasing consumer spending, which increased by 3.7%, the highest since the first quarter of 2023.
This market volatility has caused investors to seek defensive stocks that remain stable during market downturns and offer stable income through dividends and long-term growth opportunities.
Demand for healthcare amenities remains constant, as the need for medical treatments remains the same regardless of economic conditions. Hence, the sector offers investors stability and protection during market downturns. Likewise, basic utilities such as goods and services like water, gas, and electricity cannot be avoided or subset, given their necessity for survival.
Therefore, investing in defensive stocks amidst economic uncertainties is ideal due to constant consumer demand, stable income, and portfolio protection. Given these factors, let's delve deeper into the fundamentals of the top defensive stocks: JNJ, PFE, and GNE.
Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>)
JNJ researches, develops, manufactures, and sells various products in the healthcare field internationally. The company operates in the Innovative Medicine and MedTech segments. It offers products for various therapeutic areas, like immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis.
On October 28, JNJ announced results from the Phase 3 GRAVITI study of TREMFYA&#xAE; (guselkumab), the first and only IL-23 inhibitor. TREMFYA showed robust subcutaneous induction and maintenance therapy results, demonstrating significant clinical remission and endoscopic response at 48 weeks in adults with moderately to severely active CD.
Upon FDA approval, TREMFYA&#xAE; could become the first IL-23 treatment to offer a subcutaneous and intravenous (IV) induction regimen for patients with Crohn's disease (CD).
On October 9, JNJ completed the acquisition of V-Wave Ltd., a privately held company focused on developing innovative treatment options for patients with heart failure. The acquisitions added V-Wave's novel and minimally invasive Ventura&#xAE; interatrial shunt to the Johnson &amp; Johnson MedTech portfolio and will also strengthen its position in the cardiovascular disease segment.
During the nine months that ended September 30, 2024, JNJ's reported sales increased 4% year-over-year to $66.30 billion. Its <a href="https://www.investopedia.com/terms/g/grossprofit.asp#:~:text=Gross%20profit%2C%20or%20gross%20income,fluctuate%20compared%20to%20production%20output.">gross profit</a> rose 4.4% year-over-year to $45.96 billion. The company's net earnings from continuing operations of $10.64 billion and $4.83 indicate increases of 15.7% and 24.1% from the prior year's period, respectively.
Analysts expect JNJ's EPS for the fourth quarter (ending December 2024) to increase 0.9% year-over-year to $2.31, and its revenue is estimated to increase 5% year-over-year to $22.47 billion for the same quarter. Moreover, the company surpassed the consensus EPS estimates in each of the trailing four quarters.
JNJ's stock has soared 9.7% over the past month and 2.5% over the past six months to close the last trading session at $160.62.
JNJ's growth prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Stability, Quality, and Value. Within the <a href="https://stocknews.com/category/pharmaceuticals/">Medical - Pharmaceuticals</a> industry, JNJ is ranked #14 out of 160 stocks.
<a href="https://stocknews.com/stock/JNJ/">Click here</a> to access additional ratings of JNJ for Growth, Sentiment, and Momentum.
Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>)
PFE discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers medicines and vaccines in various therapeutic areas like cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and Premarin family brands.
On October 22, PFE received the U.S. FDA approval for its ABRYSVO&#xAE; (Respiratory Syncytial Virus Vaccine), a bivalent RSV prefusion F (RSVpreF) vaccine to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals between 18 and 59 years of age. ABRYSVO offers the broadest indication of the RSV vaccine in adults.
The approval was based on data from the pivotal Phase 3 trial. ABRYSVO is the first and only respiratory syncytial virus vaccine indicated for adults younger than 50. Also, the indication has now been expanded to benefit older adults and pregnant women.
Also, in the same month, PFE received FDA approval for HYMPAVZI&#x2122; (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A. The approval marked a significant advancement for people living with hemophilia A or B without inhibitors for bleed prevention.
During the third quarter that ended September 29, 2024, PFE's total revenues rose 31.2% from the prior-year quarter to $17.70 billion, of which its product revenues grew 33.1% year-over-year to $15.42 billion. The company's adjusted net income and EPS came in at $6.05 billion and $1.06 for the quarter, respectively.
The company had raised its full-year 2024 revenue guidance to a range of $61 billion to $64 billion from the prior range of $59.50 to $62.50 billion. PFE also raised its adjusted EPS guidance to a range of $2.75 to $2.95.
The consensus EPS estimate of $0.46 for the fiscal fourth quarter (ending December 2024) represents a 358% improvement year-over-year. The consensus revenue estimate of $17.36 billion for the ongoing quarter represents a 21.9% increase from last year. The company has an impressive surprise history; it surpassed the consensus EPS estimates in all of the trailing four quarters.
PFE's stock has surged 0.7% over the past six months and 3.9% over the past nine months to close the last trading session at $27.99.
PFE's bright outlook is reflected in its POWR Ratings. It has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has an A grade for Growth. It also has a B grade for Value. PFE is ranked #37 among the 160 stocks in the Medical - Pharmaceuticals industry.
<a href="https://stocknews.com/stock/PFE/">Click here</a> to access PFE's other ratings for Quality, Momentum, Stability, and Sentiment.
Genie Energy Ltd. (<a href="https://stocknews.com/stock/GNE/">GNE</a>)
GNE is engaged in the supply of electricity and natural gas to residential and small business customers internationally. The company operates in two segments, GRE and Genie Renewables. It develops, constructs, and operates solar energy projects for commercial and industrial customers.
On March 21, GNE's subsidiary, Sunlight Energy Investments, a retail energy and renewable energy solutions provider, purchased a late-stage solar development project in Hamilton, Indiana, from the project developer. The Hamilton project acquisition fits perfectly with the company's growing portfolio of solar projects, which offers long-term, stable cash flows.
GNE reported total revenue of $90.70 million for the second quarter that ended June 30, 2024, and its income from operations was $10.56 million for the same period. The company's net income attributable to Genie common stockholders and EPS came in at $9.61 million and $0.36 for the quarter, respectively.
Shares of GNE have declined marginally over the past six months to close the last trading session at $15.67.
GNE's POWR Ratings reflect its robust outlook. GNE has an overall B rating, equating to a Buy in our proprietary rating system.
The stock has a B grade for Quality, Sentiment, Momentum, and Value. It is ranked #2 among the 59 stocks in the <a href="https://stocknews.com/category/utilities-domestic/">Utilities - Domestic</a> industry.
<a href="https://stocknews.com/stock/GNE/">Click here</a> to access additional GNE ratings for Stability and Growth.Top of Form
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
JNJ shares were trading at $158.20 per share on Wednesday afternoon, down $0.15 (-0.09%). Year-to-date, JNJ has gained 3.30%, versus a 25.58% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/jnj-pfe-gne-3-defensive-stocks-to-buy-as-market-volatility-rises/>3 Defensive Stocks to Buy as Market Volatility Rises</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Defensive Stocks to Buy as Market Volatility Rises

With the rise of chronic diseases, technological advances and innovative drug pipelines are driving significant growth in the healthcare industry. Hence, investors may find long-term stability and exciting opportunities by adding stocks, Johnson & Johnson (JNJ), Pfizer (PFE), and Cigna Group (CI), to their portfolios. Read more… With a growing population and rising rates of chronic conditions, the demand for better healthcare solutions has never been greater. Thus, scooping shares of fundamentally sound healthcare stocks, Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>), Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>), and The Cigna Group (<a href="https://stocknews.com/stock/CI/">CI</a>), could provide significant gains and long-term stability.
Chronic diseases are becoming more prevalent worldwide, leading to a surge in demand for innovative treatments. As conditions like heart disease, diabetes, and respiratory issues rise, healthcare providers and pharmaceutical companies must meet the increasing need for effective and accessible solutions to manage these ailments.
That said, Artificial intelligence (AI) and machine learning are <a href="https://health.clevelandclinic.org/ai-in-healthcare">reshaping the healthcare landscape</a>. By improving task management, patient services, and complex measurements, AI is streamlining operations and accelerating the healthcare industry's growth, making it more efficient and patient centric.
Moreover, the industry continues to demonstrate its potential, as seen with the U.S. Food and Drug Administration's <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">approval of 38 new drugs</a> for chronic conditions this year. With global pharmaceutical revenue expected to <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/worldwide">hit $1.45 trillion by 2029</a>, growing at a steady CAGR of 4.7%, the future of healthcare looks promising.
With these conductive trends in mind, let us dive deep into the fundamentals of three healthcare stocks, starting with #3.
Stock #3: Johnson &amp; Johnson (<a href="https://stocknews.com/stock/JNJ/">JNJ</a>)
JNJ researches, develops, manufactures, and sells a variety of healthcare products. Its offerings address conditions such as immunology, infectious diseases, neuroscience, oncology, and pulmonary hypertension. The company operates through two segments: Innovative Medicine and MedTech.
On October 10, JNJ <a href="https://s203.q4cdn.com/636242992/files/doc_news/2024/Oct/10/final-volt-press-release-us_dps_trex_391290.pdf">announced the launch</a> of the first phase of VOLT&#x2122; Variable AngleOptimized Locking Technology Plating System, an innovative system for fracture management solutions. This positions JNJ to strengthen its presence in the orthopedic trauma market, driving market share growth and stable opportunities.
On October 9, JNJ <a href="https://www.investor.jnj.com/news/news-details/2024/Johnson--Johnson-Completes-Acquisition-of-V-Wave/default.aspx">announced the completion of acquisition</a> of V-Wave Ltd., a privately held company focused on developing innovative treatment options for patients with heart failure. The acquisition could allow JNJ to broaden its product offerings and capitalize on emerging opportunities in the growing field of heart disease management.
For the fiscal 2024 third quarter that ended on September 29, JNJ's sales to customers increased 5.2% year-over-year to $22.47 billion. Its <a href="https://www.investopedia.com/terms/g/grossprofit.asp">gross profit</a> also grew 5.2% from the year-ago value to $15.51 billion. Additionally, the company's net earnings and net earnings per share from continuing operations came in at $2.69 billion and $1.11, respectively.
Analysts expect JNJ's revenue for the fiscal year ending December 2024 to increase 4.3% year-over-year to $88.79 billion. Its EPS for the ongoing fiscal year is expected to grow marginally from the previous year to $9.96. Plus, the company topped the consensus EPS estimates in all four trailing quarters.
JNJ's stock has increased by 6.1% over the past six months, closing the last trading session at $158.35. The company maintains a 24-month beta of 0.25, reflecting its relatively low market volatility.
JNJ's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> mirror its strong fundamentals. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
JNJ has a B grade for Value, Stability, and Quality. It is ranked #14 out of 160 stocks in the <a href="https://stocknews.com/category/pharmaceuticals/">Medical – Pharmaceuticals</a> industry.
To check the stock's ratings for Growth, Sentiment, and Momentum, <a href="https://stocknews.com/stock/JNJ/">click here</a>.
Stock #2: Pfizer Inc. (<a href="https://stocknews.com/stock/PFE/">PFE</a>)
PFE is a global, research-driven biopharmaceutical company that discovers, develops, manufactures, markets, sells, and distributes biopharmaceutical products. It provides medicines and vaccines in therapeutic areas such as cardiovascular metabolic, migraine, and women's health.
On October 22, PFE <a href="https://investors.pfizer.com/Investors/News/news-details/2024/U.S.-FDA-Approves-Pfizers-RSV-Vaccine-ABRYSVO-for-Adults-Aged-18-to-59-at-Increased-Risk-for-Disease/default.aspx">announced the U.S. Food and Drug Administration (FDA) approval</a> of ABRYSVO, bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
With this approval, the company could expand its footprint in infectious disease prevention, opening doors to new opportunities and solidifying its reputation as a leader in innovative healthcare solutions.
On October 11, PFE <a href="https://investors.pfizer.com/Investors/News/news-details/2024/U.S.-FDA-Approves-Pfizers-HYMPAVZI-marstacimab-hncq-for-the-Treatment-of-Adults-and-Adolescents-with-Hemophilia-A-or-B-Without-Inhibitors/default.aspx">announced the FDA approval</a> for HYMPAVZI, a drug for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.
The approval strengthens PFE's position in the rare disease market. As the company broadens its therapeutic offerings, HYMPAVZI provides a vital tool for managing hemophilia, paving the way for increased growth in this specialized area of healthcare.
For the fiscal third quarter that ended on September 29, 2024, PFE's total revenues increased 31.2% year-over-year to $17.70 billion. The adjusted net income and adjusted earnings per common share attributable to PFE common shareholders stood at $6.05 billion and $1.06, compared to a net loss and loss per share of $968 million and $0.17 in the prior year's quarter, respectively.
Street expects PFE's revenue and EPS for the fiscal fourth quarter (ending December 2024) to increase 21.9% and 358% year-over-year to $17.36 billion and $0.46, respectively. Moreover, the company topped the consensus EPS estimates in all four trailing quarters.
PFE's stock has risen 5.3% over the last nine months, with the latest close at $27.99. The company's 24-month beta stands at 0.23, highlighting its lessened exposure to market fluctuations.
PFE's solid prospects are projected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
PFE has an A grade for Growth and a B for Value. It is ranked #37 within the Medical – Pharmaceuticals industry.
<a href="https://stocknews.com/stock/PFE/">Click here</a> to access PFE's ratings for Quality, Momentum, Stability, and Sentiment.
Stock #1: The Cigna Group (<a href="https://stocknews.com/stock/CI/">CI</a>)
CI offers insurance and related services. Its Evernorth segment provides coordinated and point-solution health services. Meanwhile, the Cigna Healthcare segment delivers medical, pharmacy, behavioral health, dental, and other products, including Medicare plans and international health coverage for individuals and employees.
On January 31, CI <a href="https://newsroom.thecignagroup.com/2024-01-31-The-Cigna-Group-to-Sell-Medicare-Businesses-and-CareAllies-to-Health-Care-Service-Corporation-HCSC">announced a definitive agreement</a> for Health Care Service Corporation (HCSC) to acquire its Medicare Advantage, Cigna Supplemental Benefits, Medicare Part D, and CareAllies businesses for an approximate transaction value of $3.7 billion. This would enable CI to unlock substantial value for stakeholders by freeing up resources to accelerate investment in its services platform.
For the fiscal third quarter that ended on September 30, 2024, CI's adjusted revenues increased 29.8% year-over-year to $63.70 billion. Its adjusted income from operations rose 5% from the year-ago value to $2.11 billion. Moreover, the company's adjusted income from operations per share rose 10.9% from the prior year's quarter to $7.51.
The consensus revenue estimate of $62.91 billion for the fiscal fourth quarter (ending December 2024) reflects a year-over-year rise of 23%. Its EPS for the same period is expected to increase 15.4% from the prior year's period to $7.84. Also, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is impressive.
CI's shares have gained 6.3% year-to-date, closing the last trading session at $318.39. The stock holds a 24-month beta of 0.13, indicating its low volatility in comparison to broader market movements.
CI's POWR Ratings reflect its sound outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
CI has a B grade for Growth, Value, and Sentiment. It has topped the 10-stock A-rated <a href="https://stocknews.com/category/health-insurance/">Medical - Health Insurance</a> industry.
To check CI's Quality, Momentum, and Stability ratings, <a href="https://stocknews.com/stock/CI/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>
<hr />
JNJ shares were unchanged in premarket trading Wednesday. Year-to-date, JNJ has gained 3.40%, versus a 22.48% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/jnj-pfe-ci-3-healthcare-stocks-for-long-term-stability-and-growth/>3 Healthcare Stocks for Long-Term Stability and Growth</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Healthcare Stocks for Long-Term Stability and Growth

Renaissance Tech adds Micron, exits Broadcom, among Q3 trades

Vaccine makers close lower amid reports RFK Jr may head HHS (update)

Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson (JNJ) with an Outperform rating and $190 price target The firm ex...

Wolfe starts J&J at Outperform, sees growth drivers as 'best-in-class'

Intuitive Surgical: The Price For Its Excellence Is Too High

AAPL

ARCC

AVGO

BNTX

COIN

CSCO

ISRG

MAIN

MSFT

NVDA

SCHD

SCHO

TCPC

TSLA

VICI

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Press Releases

Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress

New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease

Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study

AMZN

ORCL

SNOW

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Johnson & Johnson

Interés en corto

Johnson & Johnson (NYSE:JNJ) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL